Banales JM, Marin J, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.

PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

PubMed  Google Scholar 

Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221–31.

CAS  PubMed  Google Scholar 

Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–44.

CAS  PubMed  Google Scholar 

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

CAS  PubMed  Google Scholar 

Arima S, Shimizu K, Okamoto T, et al. A multicenter phase II study of gemcitabine plus S-1 chemotherapy for advanced biliary tract cancer. Anticancer Res. 2017;37(2):909–14.

CAS  PubMed  Google Scholar 

André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862–7.

PubMed  PubMed Central  Google Scholar 

Shroff RT, Guthrie KA, Scott AJ, Borad MJ, Goff LW, Matin K et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. JCO. 2023;41, LBA490. https://doi.org/10.1200/JCO.2023.41.4_suppl.LBA49

Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250–8. https://doi.org/10.1093/annonc/mdy540.

CAS  PubMed  Google Scholar 

Kato K, Sun JM, Shah MA, Enzinger PC, Adenis A, Kojima T et al. LBA8_PR - pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020; 31(suppl_4):S1142-S1215. https://doi.org/10.1016/annonc/annonc325.

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

CAS  PubMed  PubMed Central  Google Scholar 

Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–33.

CAS  PubMed  PubMed Central  Google Scholar 

Valsecchi ME. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270.

PubMed  Google Scholar 

Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–8.

CAS  PubMed  Google Scholar 

Chen X, Wu X, Wu H et al. SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: results from a single-arm exploratory study. J Clin Oncol JCO. 2019; 37(15_suppl):4092–4092.

Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother. 2019;68(9):1527–35.

CAS  PubMed  PubMed Central  Google Scholar 

Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–21.

PubMed  Google Scholar 

Li W, Wang Y, Yu Y, et al. Toripalimab in advanced biliary tract cancer. Innovation (Camb). 2022;3(4):100255.

CAS  PubMed  Google Scholar 

Burris HA 3rd, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626–35.

CAS  PubMed  Google Scholar 

Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–65.

PubMed  Google Scholar 

Vogel A, Chen L, He AR, Kim JW, Chen M-H, McNamara MG et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). J Clin Oncol.2022;40(16_suppl):4075–4075.

Sahai V, Griffith KA, Beg MS, et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer. 2022;128(19):3523–30.

CAS  PubMed  Google Scholar 

Zeng TM, Yang G, Lou C, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun. 2023;14(1):1340.

CAS  PubMed  PubMed Central  Google Scholar 

Feng K, Liu Y, Zhao Y et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2019-000367

Chiang N-J, et al. 49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer. Ann Oncol. 2021;32:S377.

Google Scholar 

Mizusawa J, Morizane C, Okusaka T, et al. Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46(4):385–8.

PubMed  PubMed Central  Google Scholar 

Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1707–12.

PubMed  PubMed Central  Google Scholar 

Liu T, Li Q, Lin Z, et al. A single-arm phase II study of nab-paclitaxel plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer. Cancer Res Treat. 2024;56(2):602–15.

CAS  PubMed  Google Scholar 

Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–30.

PubMed  PubMed Central  Google Scholar 

Suenaga M, Yamada S, Fujii T, et al. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol. 2016;113(4):413–9.

CAS  PubMed  Google Scholar 

Shi Y, Zhang S, Han Q, et al. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget. 2017;8(54):92401–10.

PubMed  PubMed Central  Google Scholar 

Zhang W, Du C, Sun Y, et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemother Pharmacol. 2018;82(4):655–60.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Sun Y, Jiang Z, Qu W, Gong C, Zhou A. Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial. Hepatobiliary Surg Nutr. 2023;12(1):37–44.

CAS  PubMed  Google Scholar 

Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L et al. LBA6_PR - nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31(suppl_4):S1142-S1215. https://doi.org/10.1016/annonc/annonc325.

McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–72.

CAS  PubMed  Google Scholar 

Addeo A, Banna GL, Weiss GJ. Tumor mutation burden-from hopes to doubts. JAMA Oncol. 2019;5(7):934–5.

PubMed  Google Scholar 

Lin J, Cao Y, Yang X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021;11(10):4585–98.

CAS  PubMed  PubMed Central  Google Scholar 

Mie T, Sasaki T, Okamoto T et al. Current status of targeted therapy for biliary tract cancer in the era of precision medicine. Cancers (Basel). 2024;16(5). https://doi.org/10.3390/cancers16050879

Valle JW, Qin S, Antonuzzo L et al. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase 3 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. 2022 ESMO ASIA. https://doi.org/10.1016/j.annonc.2022.10.104

Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–47.

CAS  PubMed  Google Scholar 

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–62.

CAS  PubMed  PubMed Central  Google Scholar 

Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–62.

PubMed  PubMed Central  Google Scholar